Oxford Nanopore

Apr 20, 2023

Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma; Oxford Nanopore and bioMérieux Signs Partnership Agreement; Boomerang Medical’s Bioelectronic Device for Inflammatory Bowel Disease; Senseonics’s ENHANCE Clinical Trial Updates; RapidAI’s Non-Contrast CT Imaging Product; FDA Clearance for Neuspera Medical’s Peripheral Nerve Stimulation System

Bausch + Lomb and Heidelberg Engineering Introduced SeeLuma™ Fully Digital Surgical Visualization Platform On April 13, 2023, Bausch + Lomb, a leading global eye health company dedicated to helping people see better and to live better, and Heidelberg Engineering, announced the introduction of the Se...

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Insights

Oxford Nanopore

Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug

Editor Picks